Scarica l'app Stockscreener
27.55
1.08%
-0.30
Dopo l'orario di chiusura:
27.55
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$27.85
Aprire:
$27.97
Volume 24 ore:
1.73M
Relative Volume:
0.38
Capitalizzazione di mercato:
$3.30B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-29.62
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
-6.16%
1M Prestazione:
+19.26%
6M Prestazione:
-59.77%
1 anno Prestazione:
-65.65%
Intervallo 1D:
$27.45
$28.73
Intervallo di 1 settimana:
$26.37
$29.73
Portata 52W:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
27.55 | 3.30B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Why Viking Therapeutics (VKTX) Stock is Gaining Today - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - Yahoo
Viking Therapeutics (VKTX) Sees Unusual Options Activity | VKTX Stock News - GuruFocus
Why Viking Therapeutics Stock Surged Nearly 20% Higher In April - Barchart.com
Why Viking Therapeutics Stock Was Victorious This Week - MSN
(VKTX) Investment Report - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Sees 20% Stock Surge Despite Financial Losses - GuruFocus
Why Viking Therapeutics (VKTX) Stock is Rising Today - GuruFocus
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking Therapeutics (VKTX) Sees Surge in Call Options Trading | VKTX Stock News - GuruFocus
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025 - simplywall.st
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - The Globe and Mail
This Soaring Stock Just Delivered More Good News. Time to Buy? - AOL.com
Where Will Viking Therapeutics Be in 3 Years? - Nasdaq
1 Beaten-Down Stock to Buy and Hold for 10 Years - Yahoo Finance
BlackRock, Inc. Reduces Stake in Viking Therapeutics Inc - GuruFocus
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - Nasdaq
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Why Viking Therapeutics Stock Popped Again Today - MSN
VKTX Stock Surges Amid Analyst Optimism on VK2735 - GuruFocus
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight By Investing.com - Investing.com India
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight - Investing.com
Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Why Viking Therapeutics (VKTX) Stock is On the Move - GuruFocus
Viking Therapeutics (VKTX) Sees Stock Rise Despite Increased Los - GuruFocus
Viking Therapeutics (VKTX) Gains Overweight Rating from Cantor F - GuruFocus
Why Viking Therapeutics Stock Popped Today - MSN
Viking Therapeutics (VKTX) Price Target Reduced Amid Competitive Obesity Market | VKTX Stock News - GuruFocus
Viking Therapeutics price target lowered to $75 from $95 at Truist - TipRanks
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - MSN
Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus - Investing.com
Viking Therapeutics Stock May Struggle After As-Expected Report - MarketBeat
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025 - simplywall.st
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):